Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Acupuncture plus sedative may shield stroke survivors from depression

NCT ID NCT07739329

Prevention Sponsor: Min Su Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial tests whether combining electroacupuncture with a sedative drug called dexmedetomidine can prevent depression in people who recently had an ischemic stroke. Participants at high risk for post-stroke depression will receive either the combined treatment, a sham version, or a placebo. The goal is to see if this integrative approach can reduce the chance of developing depression within three months after the stroke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electroacupuncture combined with intranasal dexmedetomidine
What this could lead to
If effective, this combined therapy could offer a safe way to prevent depression in people who have recently had a stroke, improving their recovery and quality of life.
What could go wrong
This is a single trial, and results may not apply to all stroke survivors. The treatments carry risks, such as bleeding or infection from needles, and sedation or low blood pressure from dexmedetomidine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 231 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ischemic stroke with a disease course of less than 2 weeks; * Patients with high-risk PSD; * The patient can accept the treatment plan described in this trial and sign the informed consent form. Exclusion Criteria: * Cognitive impairment; * Severe aphasia or significant language impairment; * Disturbance of consciousness; * History of psychiatric disorders, including but not limited to depression, schizophrenia, and bipolar disorder; * Alcohol or substance dependence; * Use of sedatives or antipsychotic medications within 2 weeks prior to screening; * Severe cardiac, hepatic, or renal dysfunction; * Complicated with acute severe conditions or unstable vital signs; * Pregnancy or lactation; * Contraindications or intolerance to electroacupuncture; * Sick sinus syndrome, severe bradycardia (heart rate \< 50 bpm), second-degree or higher atrioventricular block, permanent pacemaker implantation, severe heart failure, or ejection fraction \< 30%; * Known allergy to any of the study medications; * Inability to complete the study procedures due to any unavoidable circumstances.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post stroke depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.